Research
Pembrolizumab monotherapy effective in cSCC: results from AACR21
Pembrolizumab monotherapy has shown robust and durable antitumour activity and promising survival data in both locally advanced and recurrent/metastatic cutaneous SCC, according to an Australian oncologist.
Speaking at the American Association for Cancer Research (AACR) meeting, Dr Brett Hughes presented an...
Pembrolizumab monotherapy has shown robust and durable antitumour activity and promising survival data in both locally advanced and recurrent/metastatic cutaneous...